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The interferon (IFN)-stimulated gene 15 (ISG15) encodes one of the most abundant pro-
teins induced by interferon, and its expression is associated with antiviral immunity. To iden-
tify protein components implicated in IFN and ISG15 signaling, we compared the proteomes
of ISG15-/- and ISG15+/+ bone marrow derived macrophages (BMDM) after vaccinia virus
(VACV) infection. The results of this analysis revealed that mitochondrial dysfunction and
oxidative phosphorylation (OXPHOS) were pathways altered in ISG15-/- BMDM treated with
IFN. Mitochondrial respiration, Adenosine triphosphate (ATP) and reactive oxygen species
(ROS) production was higher in ISG15+/+ BMDM than in ISG15-/- BMDM following IFN treat-
ment, indicating the involvement of ISG15-dependent mechanisms. An additional conse-
quence of ISG15 depletion was a significant change in macrophage polarization. Although
infected ISG15-/- macrophages showed a robust proinflammatory cytokine expression pat-
tern typical of an M1 phenotype, a clear blockade of nitric oxide (NO) production and argi-
nase-1 activation was detected. Accordingly, following IFN treatment, NO release was
higher in ISG15+/+ macrophages than in ISG15-/- macrophages concomitant with a
decrease in viral titer. Thus, ISG15-/- macrophages were permissive for VACV replication
following IFN treatment. In conclusion, our results demonstrate that ISG15 governs the
dynamic functionality of mitochondria, specifically, OXPHOS and mitophagy, broadening its
physiological role as an antiviral agent.







Citation: Baldanta S, Fernández-Escobar M, Acı́n-
Perez R, Albert M, Camafeita E, Jorge I, et al.
(2017) ISG15 governs mitochondrial function in
macrophages following vaccinia virus infection.
PLoS Pathog 13(10): e1006651. https://doi.org/
10.1371/journal.ppat.1006651
Editor: Deborah J. Lenschow, Washington
University School of Medicine, UNITED STATES
Received: March 2, 2017
Accepted: September 17, 2017
Published: October 27, 2017
Copyright: © 2017 Baldanta et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This research is supported by a grant
from Spanish Ministry of Economy and
Competitiveness (MINECO) to SG (SAF2014-
54623-R), and to JV from MINECO (BIO2015-
67580-P) and from the Carlos III Institute of
Health-Fondo de Investigación Sanitaria (PRB2,
IPT13/0001—ISCIII-SGEFI/FEDER, ProteoRed).
The funders had no role in study design, data
Author summary
Protein modification by ubiquitin and ubiquitin-like proteins is a key regulatory process
of the innate and adaptive immune response. Interferon-stimulated gene 15 product
(ISG15) is an ubiquitin-like protein modifier that can reversibly attach to different viral
and cellular proteins, mediating potent antiviral responses. In turn, many viruses, includ-
ing poxviruses, have evolved strategies to antagonize the antiviral and inflammatory
effects of the innate immune response in order to keep infected cells alive until virus repli-
cation is complete. Here, we describe a novel role for ISG15 in the control of mitochon-
drial function. Post-translational modifications such as ISGylation regulate essential
mitochondrial processes including respiration and mitophagy, and influence macrophage
innate immunity signaling. These findings are clinically relevant since mitochondrial dys-
function is seen in many pathologies, such as infectious disease, cancer, and cardiovascu-
lar or neurological disorders, among others, underscoring the importance of the
relationship between cellular metabolism and immune response.
Introduction
The type I interferon (IFN) signaling system is activated following viral infection, resulting in
upregulation of interferon-stimulated genes (ISGs) that have diverse functions in the antiviral
innate immune response. ISG15 is an IFN α/β-induced ubiquitin-like protein that exists in
two distinct states: as a free molecule (intracellular and extracellular), or conjugated to lysine
residues of target proteins (ISGylation). Biochemically, ISGylation occurs in a manner similar
to ubiquitin conjugation, and is carried out in three main steps, activation, conjugation, and
ligation, which are performed by ISG15-activating enzymes, ISG15-conjugating enzymes, and
ISG15 E3 ligases, respectively [1]. As a reversible modification, ISG15 is removed from conju-
gated proteins by the ISG15-specific protease USP18 [2]. ISGylation has been shown to occur
in a cotranslational process favoring modification of viral proteins in infected cells, which in
turn obstructs virus assembly or function [3–5]. Furthermore, cellular proteins involved in
antiviral defense or trafficking of viral particles have been shown to be ISGylated, supporting
the antiviral function of ISG15 [5, 6]. Several viral proteins can be conjugated to ISG15, such
as the non-structural NS1 protein from influenza A/B virus and the human immunodeficiency
virus (HIV) Gag protein [7], which inhibits specific viral functions or virion assembly and
blocks viral progression [8, 9]. The non-structural protein of influenza B virus 1 (NS1B) has
been recently shown to antagonize ISGylation-mediated antiviral activity by binding and
sequestering ISGylated viral proteins, primarily ISGylated viral nucleoproteins, to facilitate
viral replication [10]. Moreover, ISG15 expression has been shown to disrupt the process of
virus-budding via different mechanisms such as by blocking the endosomal sorting complexes
required for transport (ESCRT machinery in HIV-infected cells) [11], or by inhibiting Nedd4
E3 ubiquitin ligase activity in the case of Ebola and other enveloped viruses [12].
Studies in mice have demonstrated a credible role for ISG15 in antiviral immunity. Accord-
ingly, mice lacking ISG15 have enhanced susceptibility to several pathogens including viruses
[13] and bacteria [14, 15], and this phenotype is rescued in USP18-mutant mice in which high
levels of ISG15 conjugates are observed [16]. By contrast, human ISG15 has essential immune
functions, but not in antiviral immunity. Specifically, free extracellular human ISG15 is crucial
for IFN-γ-dependent antimycobacterial immunity [17], while free intracellular ISG15 is
important for USP18-mediated downregulation of IFN-α/β signaling [18]. A recent
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publication has demonstrated that ISG15 deficiency is related to increased viral resistance in
humans, but not in mice [19].
Our previous work demonstrated that ISG15 plays an important role in vaccinia virus
(VACV) infection [20, 21], and in the regulation of macrophage responses. Accordingly,
ISG15-/- macrophages display reduced activation, phagocytic capacity and programmed cell
death in response to VACV infection [22]. In addition to the antiviral role associated with
ISGylation, we also showed that ISG15 secreted by tumor-associated macrophages plays a criti-
cal support role for pancreatic cancer stem cells [23]. Macrophages are specialized antigen pre-
senting cells that have important functions in innate defense against infection, in clearance of
host infected cells and molecules, and in viral antigen presentation [24]. Macrophages are
characterized by high phenotypic plasticity including the ability to polarize to an “activated or
M1” or an “alternatively-activated or M2” form in response to environmental signals (reviewed
in [25, 26]). M1 macrophages are defined by their strong inflammatory cytokine secretion and
production of NO, resulting in an effective pathogen killing mechanism [27, 28]. By contrast,
M2 macrophages have high phagocytic capacity and promote tissue repair/remodeling during
wound healing.
Mitochondria have recently been shown to have essential roles in the immune system, par-
ticularly in regulating macrophage responses to pathogen infections [29], tissue damage and
inflammation. Consequently, defects in macrophages functionality can lead to chronic inflam-
mation in different animal models [30]. Polarization of macrophages to pro-inflammatory
(M1) or anti-inflammatory (M2) phenotypes results in distinct metabolic reprogramming,
which corresponds to the progression or resolution of inflammation, respectively. Moreover,
mitochondria regulate other mechanisms that are important for the response to viral infection,
such as apoptosis, and there is evidence that the regulation of cell death in the mitochondrial-
mediated antiviral immunity depends on their metabolism.
In the present study, we observed that several proteins from mitochondria are ISGylated,
and that ISG15 regulates multiple mitochondrial processes including metabolism and mito-
phagy, a specialized form of autophagy involving the selective degradation and recycling of
mitochondria. We also found that ISG15 modulates macrophage polarization, which has been
shown to be dependent on cellular metabolism [31], suggesting that the antiviral effect of
ISG15 may also be due to the fine regulation of its polarization. In summary, we demonstrate
that ISG15 regulates the functionality and stability of mitochondria, which are essential for cel-
lular homeostasis. Given the large number of pathologies associated with mitochondrial dys-
function, including infectious diseases, heart damage, mental disorders and cancer, among
others, the elucidation of the mechanisms by which ISG15 controls this organelle is an impor-
tant future challenge.
Results
ISG15 controls cellular metabolism and mitochondrial activity
It has been previously shown that several macrophage mitochondrial proteins are specific tar-
gets of ISGylation [14, 32], suggesting an important role for ISG15 in mitochondria of these
cells. We therefore sought to explore the involvement of ISG15 in mitochondrial metabolism
in macrophages. To gain a comprehensive overview of cellular protein dynamics regulated by
ISG15, we analyzed total proteomes of murine IFN-treated bone marrow-derived macro-
phages (BMDM) from ISG15+/+ and ISG15-/- mice. As illustrated in Fig 1, the absence of
ISG15 led to a change in the expression of specific molecules involved in several functions
including OXPHOS, mitochondrial dysfunction, phagocytosis, integrin signaling, cellular traf-
ficking and ubiquitin modifications. Of particular interest was the observation that expression
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Fig 1. Comparative proteomics analysis of ISG15-/- versus ISG15+/+ IFN-treated BMDM. Ingenuity pathway analysis showing selected canonical
pathways differently modulated in ISG15-/- versus ISG15+/+ positives values IFN-treated BMDM (p < 0.05). Percentage of proteins down- or up-regulated
in selected canonical pathways differently modulated in ISG15-/- versus ISG15+/+ BMDM after pretreatment with IFN (500 units/ml, 16 hours) (p < 0.05).
https://doi.org/10.1371/journal.ppat.1006651.g001
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levels of several proteins related to OXPHOS and oxidative stress response differed between
ISG15+/+ and ISG15-/- BMDM, pointing to the involvement of ISG15 in these mitochondrial
processes (Table 1).
To investigate the role of ISG15 and ISGylation in macrophages, we evaluated the presence
of ISGylated proteins in total extracts from ISG15+/+ and ISG15-/- BMDM infected or not with
VACV, or pre-treated or not with IFN. A clear increase in ISGylation levels was observed in
IFN-treated ISG15+/+ BMDM but not in equivalent non-treated VACV-infected cells (Fig 2A).
To characterize further the subcellular localization of these proteins, we evaluated in unin-
fected BMDM ISGylation in total, or cytoplasmic or mitochondrial proteins extracts. We
observed ISGylated proteins in all fractions and their levels increased following IFN pre-treat-
ment (Fig 2B). As the proteomic study indicated that several mitochondrial processes were
regulated by ISG15 (Table 1), we focused our attention on this organelle. In concordance with
our data, a clear activation of ISG15 in the mitochondrial proteome of cells infected with influ-
enza virus has been previously reported [33], demonstrating a causal link between mitochon-
dria and ISG15. To study the intra-mitochondrial localization of the ISGylated proteins, we
performed proteinase K assays using isolated mitochondria, and thus only proteins localized
in the outer membrane are sensitive to proteolytic cleavage. The majority of the ISGylated pro-
teins were resistant to proteinase K (PK) (Fig 2C), indicating a possible localization in the
intermembrane compartment (IC), inner membrane (IM) or in the matrix. The same result
was found for mitochondria isolated from IFN-treated cells, albeit with an elevated expression
of ISGylated proteins (Fig 2C). To examine deeper if ISG15 and ISGylated proteins localized,
we performed a PK digestion combined with digitonin permeabilization in isolated mitochon-
dria as previously described [34]. In addition, we performed a PK assay with osmotic shock
(OS) with or without Triton X-100 as was described [35]. We used TOMM20 as an OM,
TIMM23 as an IM and SOD2 as a matrix protein as controls of the indicated mitochondrial
compartments. The experiments depicted in Fig 2D showed that ISG15 and ISGylated proteins
displayed resistance to PK treatment in isolated mitochondria, but became accessible to prote-
ase digestion at elevated digitonin concentration and also when the OM was disrupted by OS.
The integrity of the mitochondria was lost when we incubated it with OS and TritonX-100,
this was the unique condition in which SOD2 localized in the matrix was accessible to PK [36].
Consequently, we concluded that the localization of monomeric ISG15 is localized in the IC,
and ISGyated proteins can be localized mostly in the IC or IM but also in the matrix (Fig 2D).
To assess the role of ISG15 in mitochondria in more detail, we first analyzed the metabolic
consequences of ISG15 deletion in BMDM by measuring respiratory parameters with the Sea-
horse Biosciences Flux Analyzer platform. We measured the oxygen consumption rate (OCR)
in non-infected or infected ISG15+/+ and ISG15-/- BDBM treated or not with IFN to gauge
mitochondrial OXPHOS. Basal OCR is an indicator of the normal respiration rate of cells in
physiological conditions, whereas maximal OCR is reached following stimulation of the mito-
chondrial electron transport chain (ETC) with a potent protonophore such as carbonyl cya-
nide-4-(trifluoromethoxy)phenylhydrazone (FCCP). In non IFN-treated cells, similar
respiration levels were observed in ISG15+/+ and ISG15-/- BMDM uninfected or at early times
post-infection. However, following IFN treatment, both basal and maximal OCR levels in
non-infected ISG15+/+ cells were significantly higher than those in non-infected ISG15-/-
BMDM (Fig 3A and 3B). At 2 hours post-infection (hpi), respiratory levels were slightly
reduced in ISG15-/- BMDM (Fig 3A and 3B), but at later stages there was a similar decrease in
the OCR (both basal and FCCP-induced) in both populations, indicating that viral infection
reduces OXPHOS (S1 Fig).
In agreement with the reduction in OXPHOS, a clear decrease in mitochondrial ATP pro-
duction was observed in IFN-treated ISG15-/- BMDM when compared with ISG15+/+ BMDM
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Table 1. Representative protein abundance changes in the ISG15 -/- vs ISG15+/+ comparison in BMDM. Positive/negative values indicate increased/
decreased abundance in ISG15-/- as compared to ISG15+/+.
Ingenuity Canonical Pathways Symbol Description Standardized log2 (Fold
change)
ISG15 Ubiquitin-like protein ISG15 -18,42
Apoptosis signaling FSCN1 Fascin 4,68
BAK Bcl-2 homologous antagonist/killer 4,50
CYC Cytochrome c, somatic 4,20
SPTN1 Spectrin alpha chain, non-erythrocytic 1 3,53
KPCA Protein kinase C alpha type 3,15
CAN1 Calpain-1 catalytic subunit 2,10
MK01 Mitogen-activated protein kinase 1 -2,40
B2L11 Bcl-2-like protein 11 -2,69
ACINU Apoptotic chromatin condensation inducer in the nucleus -2,80
MK03 Mitogen-activated protein kinase 3 -3,02
BIR1A Baculoviral IAP repeat-containing protein 1a -3,04
MCL1 Induced myeloid leukemia cell differentiation protein Mcl-1 homolog -3,31
BAX Apoptosis regulator BAX -3,56
IKBB NF-kappa-B inhibitor beta -3,57
PLCG2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 -3,98
BID BH3-interacting domain death agonist -4,06
NFKB2 Nuclear factor NF-kappa-B p100 subunit -4,27
KS6A1 Ribosomal protein S6 kinase alpha-1 -4,55
CAN2 Calpain-2 catalytic subunit -5,50
MP2K2 Dual specificity mitogen-activated protein kinase kinase 2 -5,58
MP2K1 Dual specificity mitogen-activated protein kinase kinase 1 -12,29
Autophagy LAMP1 Lysosome-associated membrane glycoprotein 1 -2,14
STX17 Syntaxin-17 -2,27
VPS11 Vacuolar protein sorting-associated protein 11 homolog -2,75
ATG3 Ubiquitin-like-conjugating enzyme ATG3 -2,81
ATG7 Ubiquitin-like modifier-activating enzyme ATG7 -2,90
VPS18 Vacuolar protein sorting-associated protein 18 homolog -4,55
SQSTM Sequestosome-1 -8,90
Mitochondrial Dysfunction AOFA Amine oxidase [flavin-containing] A 16,29
ACON Aconitate hydratase, mitochondrial 10,94
ODO1 2-oxoglutarate dehydrogenase, mitochondrial 10,07
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform 8,31
GSHR Glutathione reductase, mitochondrial 8,25
PRDX5 Peroxiredoxin-5, mitochondrial 7,56
GPDM Glycerol-3-phosphate dehydrogenase, mitochondrial 7,24
VDAC1 Voltage-dependent anion-selective channel protein 1 7,05
SODM Superoxide dismutase [Mn], mitochondrial 6,76
VDAC3 Voltage-dependent anion-selective channel protein 3 4,79
FIS1 Mitochondrial fission 1 protein 4,20
VDAC2 Voltage-dependent anion-selective channel protein 2 3,79
ODPA Pyruvate dehydrogenase E1 component subunit alpha, somatic form,
mitochondrial
3,70
HCD2 3-hydroxyacyl-CoA dehydrogenase type-2 3,51
MK09 Mitogen-activated protein kinase 9 -2,95
PARK7 Protein deglycase DJ-1 -4,58
PSN2 Presenilin-2 -5,58
LRRK2 Leucine-rich repeat serine/threonine-protein kinase 2 -8,69
Mitochondrial Dysfunction and apoptosis signaling AIFM1 Apoptosis-inducing factor 1, mitochondrial 5,48
CASP8 Caspase-8 -3,74
CASP3 Caspase-3 -3,77
Oxidative Phosphorylation CYC2 Cytochrome c, testis-specific 2,49
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Table 1. (Continued)
Mitochondrial Dysfunction and Oxidative
Phosphorylation
NDUB2 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial 40,54
SDHB Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 9,34
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 8,30
ATPA ATP synthase subunit alpha, mitochondrial 8,15
ATPB ATP synthase subunit beta, mitochondrial 7,48
ATPG ATP synthase subunit gamma, mitochondrial 6,74
QCR1 Cytochrome b-c1 complex subunit 1, mitochondrial 5,74
QCR7 Cytochrome b-c1 complex subunit 7 5,73
NDUAA NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10,
mitochondrial
5,38
QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial 5,15
ATP5J ATP synthase-coupling factor 6, mitochondrial 4,90
NDUS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 4,80
NDUS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 4,76
NDUV3 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial 4,71
QCR9 Cytochrome b-c1 complex subunit 9 4,69
NDUS8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial 4,61
AT5F1 ATP synthase F(0) complex subunit B1, mitochondrial 4,59
ACPM Acyl carrier protein, mitochondrial 4,53
NDUA4 Cytochrome c oxidase subunit NDUFA4 4,52
ATPO ATP synthase subunit O, mitochondrial 4,51
ATP5H ATP synthase subunit d, mitochondrial 4,24
CYC Cytochrome c, somatic 4,20
COX2 Cytochrome c oxidase subunit 2 4,16
C560 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 3,97
NDUV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 3,81
NDUA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 3,65
QCR8 Cytochrome b-c1 complex subunit 8 3,50
NDUS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial 3,41
CY1 Cytochrome c1, heme protein, mitochondrial 3,40
NDUAD NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 3,38
NDUS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial 3,29
CYB Cytochrome b 3,10
NDUS7 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial 3,01
NDUS4 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial 2,96
NDUBA NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 2,92
ATP5L ATP synthase subunit g, mitochondrial 2,89
NU4M NADH-ubiquinone oxidoreductase chain 4 2,89
COX5A Cytochrome c oxidase subunit 5A, mitochondrial 2,83
NDUA6 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 2,61
COX1 Cytochrome c oxidase subunit 1 2,60
NDUB5 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial 2,58
NDUA7 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 2,57
NDUA3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 2,40
NDUB8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial 2,38
ATPK ATP synthase subunit f, mitochondrial 2,28
NDUA8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 2,16
COX41 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 2,13
NDUA9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9,
mitochondrial
2,10
AT5G1 ATP synthase F(0) complex subunit C1, mitochondrial 2,09
ATP5E ATP synthase subunit epsilon, mitochondrial 2,07
ATPD ATP synthase subunit delta, mitochondrial 2,06
https://doi.org/10.1371/journal.ppat.1006651.t001
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Fig 2. ISGylation in non-treated or IFN-treated ISG15+/+ or ISG15-/- BMDM infected or not with VACV.
(A) ISG15+/+ and ISG15-/- BMDM pretreated or not with IFN (500 units/ml, 16 hours) were infected (1 PFU/
cell) with VACV and total protein extracts collected at mock, 2, 6 and 24 hpi and were fractionated by 12%
SDS-PAGE, transferred to nitrocellulose membranes, and incubated with anti-ISG15 antibody. Molecular
weights (MWs) are indicated. (B). Total or cytoplasmic or mitochondria protein extracts from ISG15+/+ and
ISG15-/- BMDM pretreated or not with IFN (500 units/ml, 16 hours) were obtained (20 μg) and were
Mitochondrion, interferon, ISG15
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(Fig 3C). When we measured the extracellular acidification rate (ECAR) as an index of glycoly-
sis and lactate production, we observed no differences between ISG15+/+ and ISG15-/- BMDM
(Fig 3D). Consistent with this finding, acidification rates of the culture medium for a period of
up to 48 h were similar irrespective of the carbon source (glucose vs galactose) or the infection
status, as assessed by color shift of the culture medium (S2 Fig). Furthermore, no major differ-
ences in the amount of mitochondrial deoxyribonucleic acid (DNA) (Fig 3E) or in the citrate
synthase activity (Fig 3F), were observed between ISG15+/+ and ISG15-/- BMDM when we
compared the ratio changes compared the IFN- to non IFN-treated, suggesting that the
amount of mitochondrial genome was unaltered after IFN treatment.
The mitochondrion is a major source of ROS. Superoxide (O2•−) is generated under spe-
cific bioenergetic conditions at several sites within the ETC [37]. When we evaluated whether
ISG15 could have an effect on ROS production, we observed that ROS levels (assessed by Mito-
SOX) were increased after IFN treatment by an ISG15-dependent mechanism. Accordingly,
ROS levels in non-infected IFN-treated ISG15-/- BMDM were significantly lower than in
equivalent ISG15+/+ BMDM (Fig 3G). When we measured ROS levels after infection, we found
an increase only in ISG15-/- BMDM (Fig 3G), indicating that following VACV infection ROS
accumulation occurs in ISG15-/- cells. These discrepancies in the ROS production in ISG15+/+
vs ISG15-/- BMDM production may be due to a disturbance in the ETC, generating a different
source of oxidative stress. To determine whether ISG15 or ISGylation impacts the mitochon-
dria respiratory chain, we analyzed the ETC organization of ISG15+/+ or ISG15-/- BMDM
treated or not with IFN. For that, we performed blue-native (BN)-PAGE analysis of mitochon-
drial extract (100 μg) and we observed several differences in the ETC components from
ISG15-/- mice in comparison to the WT (Fig 3H): (i) an absence of free complex I (CI); (ii) the
presence of an upper band close to the supercomplex (SC) (I+III2) and (iii) the presence of a
clear upper band close to the complex II (CII). This result indicated that the absence of ISG15
has an effect on mitochondrial complexes and supercomplexes rearrangements.
Mitochondria are dynamic organelles that continuously remodel to regulate their activity
and to maintain integrity. These events include fission (mitochondrial fragmentation) and
fusion (mitochondrial elongation), which control processes such as OXPHOS and apoptosis.
Moreover, mitochondrial dynamics regulates mitophagy, as the number of mitochondria
within cells is regulated by the equilibrium between biogenesis [38] and the removal of dam-
aged mitochondria. Given that the proteomic study revealed autophagy as a cellular category
significantly activated by ISG15 (Fig 1 and Table 1), we chose to analyze several autophagy/
mitophagy markers by western blotting. After IFN treatment, a clear decrease in the steady-
state levels of autophagy- related gene (ATG) 3, ATG5, ATG7 and light chain 3B protein
(LC3B) was observed in ISG15-/- cells irrespective of VACV infection compare to those in
ISG15+/+ (Fig 4A and S3 Fig), indicating that ISG15 affects mitophagy in addition to mito-
chondrial respiration. Collectively, these data allow us to speculate that the mitophagy
impairment in ISG15-/- BMDM might be linked to the increase in ROS levels observed after
fractionated by 12% SDS-PAGE, transferred to nitrocellulose membranes, and incubated with anti-ISG15,
anti-SOD2 (specific mitochondrial control) or anti-actin (specific cytoplamatic control) antibodies. MWs are
indicated. (C) Validation of the localization of ISGylated proteins by proteinase K treatment of intact
mitochondria. A total of 15 μg of hypotonically isolated mitochondria from ISG15+/+ or ISG15-/- BMDM, IFN
treated or not, were analyzed by western blotting (as above) using an ISG15 antibody. As a control of
protease activity, TOMM20 levels were measured. Molecular weights are indicated. (D) Isolated mitochondria
from ISG15+/+ BMDM were subjected to proteinase K (50 μg/ml) combined with digitonin permeabilization,
osmotic shock and 1% Triton X-100 incubation. After treatments as indicated, proteinase K activity was
blocked with PMSF (2 mM) and proteins extracts were subjected to SDS-PAGE and western blotting analysis
using antibodies against TOMM20, TIMM23, SOD2 and ISG15. MWs are indicated.
https://doi.org/10.1371/journal.ppat.1006651.g002
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Fig 3. Characterization of the energy metabolism of VACV-infected ISG15+/+ or ISG15-/- BMDM. ISG15+/+ or
ISG15-/- BMDM pretreated or not with IFN (500 units/ml, 16 hours) were infected (1 PFU/cell) with VACV at the times
indicated. (A-B) Basal and maximal OCR rates were monitored using the Seahorse Biosciences extracellular flux
analyzer. Results represent the mean ± the standard deviation of 4 biological replicates. (C) Mitochondrial ATP
production was measured as indicated in materials and methods. (D) ECAR rates were monitored using the Seahorse
Biosciences extracellular flux analyzer. (E) Variation of the mtDNA levels (MitoF) relative to nuclear DNA (B2) after IFN
Mitochondrion, interferon, ISG15
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VACV infection. Optic atrophy protein 1 (OPA1) is a major regulator of both mitochondrial
dynamics and bioenergetics [39], and its level was elevated in IFN-treated ISG15-/- regarding
to those in ISG15+/+ macrophages, as detected by proteomics or western blotting (Fig 4B and
S3 Fig). This finding suggests that ISG15 also controls mitochondrial fragmentation.
Mitophagy entails the formation of a double-membrane autophagosome and subsequent
degradation of mitochondria by specific autophagy-lysosome pathways [40]. To study the
mechanism by which ISG15 controls mitophagy, we first assessed the subcellular localization
of the aggresome marker p62 because of its importance for the integration of mitochondrial
and lysosomal biogenesis [41]. In the absence or presence of IFN treatment, no differences in
p62 localization were observed between ISG15+/+ and ISG15-/- non-infected BMDM. However,
using a specific antibody that recognized the oxidative phosphorylation complex IV (COX4),
an elongated mitochondrial morphology and an increase in the signal was observed in IFN-
treated ISG15-/- in comparison to those in ISG15+/+ cells (Fig 4C). These results were in line
with the increased OPA1 levels and the reduced autophagy/mitophagy makers’ levels in
ISG15-/- observed in Fig 4A and 4B, and also with the increase in the supercomplexes detected
by BN-PAGE (Fig 3F). Also we studied the oxidative phosphorylation complex IV protein lev-
els by western blot in cytoplasmic or mitochondrial subcellular fractions from ISG15+/+ or
ISG15-/- BMDM treated or not with IFN. As is illustrated in Fig 4D, taking into account that
the total protein levels loaded into the gel were similar in all the lines, a clear increase in COX4
and VDAC protein was observed in ISG15-/- BMDM, validating the result observed by micros-
copy (Fig 4C) and the proteomic analysis (Table 1). We next questioned whether ISGylation
has a role in mitophagy mediated by Parkin, an E3 ubiquitin ligase that promotes degradation
of dysfunctional mitochondria [42]. We first analyzed the protein levels of Parkin in cyto-
plasmic and mitochondrial fractions of BMDM from ISG15+/+ and ISG15-/- mice treated or
not with IFN. A clear increase of Parkin protein levels was observed after IFN treatment exclu-
sively in ISG15+/+ cytoplasmic and mitochondrial extracts. Surprisingly, in mitochondrial frac-
tion from ISG15-/- BMDM (with or without IFN treatment) Parkin levels were dramatically
reduced (Fig 4D).
ISG15 controls macrophages polarization and NO production. Cellular metabolism is
implicated in macrophage polarization [31]. Particularly, classic (M1) versus M2 macrophage
activation involves the expression of specific networks of metabolic enzymes intended to meet
the energy demands of the activated cells [31]. M1 activation is associated with higher aerobic
glycolysis and extracellular acidification rates, whereas M2-regulated gene transcription is
implicated in mitochondrial metabolism and oxidative glucose metabolism [43, 44]. To study
whether mitochondrial dysfunction correlated with changes in macrophage polarization after
VACV infection, we analyzed BMDM phenotypes following exogenous polarization using spe-
cific treatments. After triggering specific M1 or M2 polarization, we observed that both
ISG15+/+ and ISG15-/- BMDM presented the same levels of inducible nitric oxide synthase
treatment in ISG15+/+ or ISG15-/- BMDM was quantified by real time PCR. For each condition, the data represent the
ratio of mitochondrial DNA in untreated vs those after IFN treatment. Each point represents 3 independent samples
measured in duplicate (F) Citrate synthase activity after IFN treatment in ISG15+/+ or ISG15-/-. In total cell extracts from
ISG15+/+ or ISG15-/- the citrate synthase activity was measured by spectrophotometric procedure. Each point
represents 3 independent samples measured in duplicate. (G) ROS production was analyzed by fluorescence
microscopy using MitoSOX Red in Mock or VACV-infected ISG15+/+ or ISG15-/- IFN-treated or not BMDM. At the
indicated times post-infection, relative ROS production was quantified using ImageJ software and represented as the
relative fluorescence value in relation to that in non-infected cells. Significance was tested using a two-tailed t test
assuming non-equal variance. In all cases p < 0.01. (H) Analysis of the electronic transport chain (ETC) complex.
Isolated mitochondria from ISG15+/+ or ISG15-/- BMDM pretreated or not with IFN (500 units/ml, 16 hours) were
subjected to a blue native gel and the presence of the chain complex were analyzed using the following specific
antibodies: anti-CORE2 for the complex III, anti- NDUFA9, for complex I and ant-SDHA for complex II.
https://doi.org/10.1371/journal.ppat.1006651.g003
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Fig 4. Mitophagy activity of ISG15+/+ and ISG15-/- BMDM. (A) ISG15+/+ or ISG15-/-BMDMs treated or not with IFN (500
units/ml, 16 hours) were infected (1 PFU/cell) with VACV at the times indicated. Cellular lysates were analyzed by 12 or
7.5% SDS-PAGE followed by transfer to nitrocellulose membranes. The expression of ATG3, ATG5, ATG7, LC3B and β-
actin (protein loading control) was detected by western blotting using specific antibodies. Molecular weights are indicated.
(B) Altered levels of mitochondrial dynamism in ISG15-/- BMDM. ISG15+/+ or ISG15-/- BMDMs treated or not with IFN (500
units/ml, 16 hours) were infected (1 PFU/cell) with VACV at the times indicated. Cellular lysates were analyzed by 12 or
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(iNOS) (M1 marker) and arginase-1 (Arg-1; M2 marker) protein by western blotting, indepen-
dently of infection and of the presence of ISG15 (S4 Fig). By contrast, in VACV-infected non-
polarized macrophages, iNOS expression was undetectable in both cell types and Arg-1 levels
were considerably increased, especially in IFN-treated ISG15-/- BMDM (Fig 5A). The differ-
ences detected in Arg-1 protein levels were validated by measuring enzymatic Arg-1 activity
(the hydrolysis of L-arginine to urea), showing that the absence of ISG15 was accompanied by
an increase in Arg-1 activity (Fig 5B). In relation to the increased levels of Arg-1 protein in
ISG15-/- BMDM, microarray analysis of IFN-treated and VACV-infected (6 h) ISG15+/+ and
ISG15-/- peritoneal macrophages revealed an increase in Arg-1 messenger ribonucleic acid
(mRNA) levels in ISG15-/- cells, confirming the finding in BMDM (S1 Table). In addition,
VACV-infected ISG15-/- BMDM presented an increase in the mRNA levels of the inflamma-
tory cytokines tumor necrosis factor alpha (TNF-α), interferon beta (IFN-β), interleukin-6
(IL-6), interleukin-1 beta (IL-1β) and interleukin-12 (IL-12) (Fig 5C) and as measured by
ELISA (Fig 5D), which was more marked following IFN treatment, (Fig 5C and 5D). The liter-
ature suggests that these cytokines are produced primarily by M1 macrophages and are com-
monly accompanied by an increase in NO production (4).
To explore whether the alterations in macrophage polarization impacted on VACV replica-
tion, we measured viral production by the plaque assay in ISG15+/+ and ISG15-/- BMDM
treated or not with IFN. In the absence of IFN treatment, VACV was able to grow in ISG15+/+
and ISG15-/- BMDM at similar levels; however, viral production was slightly but significantly
reduced following IFN treatment of ISG15+/+ BMDM (Fig 6A). By contrast, viral replication
was unaltered in ISG15-/- cells after IFN treatment. These results suggest that IFN-induced
upregulation of ISG15 has a potential antiviral role by diminishing viral titers. A possible
explanation for the relatively small decrease in viral titer could be that BMDM are resistant to
VACV infection. As shown in Fig 6A, with a virus input of 105 plaque-forming units (PFU)/
cell (MOI 1), viral load reached only 107 PFU/ml at 24 hpi. Considering that the VACV infec-
tion efficiency in BMDM is low, we believe that the decrease in titer after IFN treatment is rele-
vant. Nevertheless, as a complementary approach to measure VAVC replication in BMDM, we
used VACV labeled with YFP, which allowed us to follow viral progression confirmed our pre-
vious results. (S5 Fig). Collectively, these experiments confirm that whereas VACV is able to
grow in BMDM, it is sensitive to IFN via a mechanism that is dependent on ISG15.
Finally, we asked whether the differences observed in proinflammatory cytokine produc-
tion impacted on the production of NO. We thus measured NO levels in supernatants from
ISG15+/+ and ISG15-/- BMDM treated or not with IFN, before and after infection. A clear
increase in NO production was observed following IFN treatment in ISG15+/+ BMDM, which
was maintained after infection (Fig 6B). By contrast, IFN treatment failed to increase NO levels
in ISG15-/- macrophages (Fig 6B), suggesting that IFN treatment provokes an increase in NO
production via an ISG15-dependent mechanism. To question whether the differences in viral
titer between IFN-treated ISG15+/+ and ISG15-/- BMDM were due to differences in NO levels,
7,5% SDS-PAGE, transferred to nitrocellulose membranes and the expression of OPA1, SDHA and tubulin (protein loading
control) were detected by Western blot using specific antibodies. MWs are indicated. (C) Subcellular COX4 and p62
localization. Uninfected ISG15+/+ or ISG15-/- BMDMs treated or not with IFN (500 units/ml, 16 hours) were fixed and
stained using a specific COX4 and p62 antibodies post-infection. 4 ’,6-diamino-2-fenilindol (DAPI) was used to stain DNA
(blue). Cells were visualized by confocal immunofluorescence microscopy. The images show representative fields (×73
magnification). (D) Validation of mitochondrial protein in cytoplasmic or mitochondrial protein extracts from BMDM from
IFN-treated or not ISG15+/+ or ISG15-/- mice (20 μg). Proteins were fractionated by 12% SDS-PAGE, transferred to
nitrocellulose membranes, and incubated with anti-TOMM20, anti-COX4, anti-Parkin or anti-VDAC proteins. Total protein
loaded into the gel is visualized after Ponceau staining. The asterisks are signal specific for the protein molecular weight
marker used. Molecular weights are indicated.
https://doi.org/10.1371/journal.ppat.1006651.g004
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Fig 5. IFN and VACV infection increases proinflammatory cytokine levels in ISG15-/- BMDM and increases arginase-1
activity. (A) ISG15+/+ or ISG15-/- BMDM were infected with VACV (1 PFU/cell). Cellular lysates collected at 2 and 6 hpi, or from
mock-infected cultures, were analyzed by 12% SDS-PAGE, transferred to nitrocellulose membranes, and the expression of iNOS,
Arg-1, ISG15 or β-actin (protein loading control) was examined by western blotting using specific antibodies. Uninfected M1 or M2
polarized ISG15-/- BMDM were used as iNOS or Arg-1 controls. (B) Under the same conditions as above, the production of urea
was measured as a marker of Arg-1 activity. The reaction was performed following the indications of the manufacturer. Results
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we added L-arginine (an iNOS substrate) to the culture medium and followed the viral pro-
gression and NO production. In IFN-treated ISG15+/+ macrophages, addition of L-arginine
increased NO levels (compare Fig 6B and 6D), which correlated with a reduction in the viral
titer (compare Fig 6C and 6D), indicating that ISG15 is an essential requirement in BMDM
for proper NO production, with functional consequences for VACV proliferation.
Discussion
Viruses exploit host cell metabolic resources to obtain energy and components required for
replication. Changes in cellular metabolism correlate with viral infection efficacy, and a link
has been established between the innate immune response and the host metabolic status [45].
Macrophages have a major role in the immune system as antimicrobial effectors that can regu-
late the adaptive immune response. Macrophages are polarized by microenvironmental signals
to distinct functional programs, and L-arginine metabolism is a key aspect in this process as it
acts as a substrate for two competing enzymes, iNOS and Arg-1. Macrophage M1 polarization
and L-arginine metabolism by iNOS is characterized by an increase in glycolysis and a
decrease in OXPHOS. By contrast, L-arginine metabolism by Arg-1 (M2 phenotype) is charac-
terized by high levels of mitochondrial OXPHOS, fatty acid oxidation and augmented ATP
synthesis [46, 47]. In this context, levels of OXPHOS in macrophages could also be used as an
indicator of differential polarization and a determinant factor for viral progression. Mitochon-
dria are multifunctional organelles with diverse roles including energy production and distri-
bution, apoptosis and host immune response induction. It is increasingly evident that
mitochondria have key roles in innate immune response against viral infections, and an associ-
ation exists between mitochondrial metabolism and viral growth [48, 49]. Moreover, viruses
manipulate mitochondrial processes to promote replication and produce progeny [50].
ISG15 is one of the most abundantly upregulated ISGs, and induces a post-translational
modification termed ISGylation that conjugates ISG15 molecules to lysine residues of de novo
synthesized viral or cellular proteins [1]. ISGylation can exert an antiviral pressure against
some infections as has been described in vitro and/or in vivo for both DNA and RNA viruses
[51, 52].
Here, we show that IFN and ISG15 have an essential role in regulating mitochondria func-
tionally and specifically IFN increases mitochondrial proteins ISGylation (Fig 2). The mecha-
nism by how the mitochondrial proteins are modified needs to be elucidated, because it can
occur directly in the mitochondrial interior or in the cytoplasm. Although, we cannot rule out
that ISGylation occurs in the mitochondria, for which all machinery should enter into the
organelle considering that ISGylation is a cotranslational process, our hypothesis is that ISGy-
lation occurs in the cytoplasm and once the mitochondrial proteins are modified, enter the
mitochondria.
A proteomic analysis revealed that several mitochondrial pathways as mitochondrial dys-
function and OXPHOS were regulated by ISG15 (Fig 1). When we analyzed several mito-
chondrial related functions we observed that specifically, OXPHOS (Fig 3A) and mitophagy
(Fig 4) were decrease in macrophages deficient in ISG15 and mitochondrial ROS production
(Fig 3G) and macrophage polarization after VACV infection differs between ISG15-/- and
represent the mean ± the standard deviation of five biological replicates. (C) The expression level of TNF-α, IFN-β, IL-6, IL-1β and
IL-12 genes was measured by quantitative RT-PCR. Triplicate samples were measured in three independent experiments; data
shown is representative of one experiment. (D) IL-6 levels in the medium of ISG15+/+ and ISG15-/- BMDM were quantified by
ELISA. Aliquots (100 μl) of supernatant from ISG15+/+ or ISG15-/- BMDM uninfected or at 2, 6, hpi were used for ELISA according
to the manufacturer’s instructions. Triplicate samples were measured in two independent experiments.
https://doi.org/10.1371/journal.ppat.1006651.g005
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Fig 6. Effect of IFN on virus replication and NO production in VACV-infected ISG15+/+ and ISG15-/- BMDM.
(A) One-step VACV growth on infected (1 PFU/cell) ISG15+/+ or ISG15-/- BMDM treated or not treated with IFN
(500 units/ml, 16 hours). Cells were infected and at the times indicated cells were harvested and virus progression
was determined by plaque assay. Results represent the mean ± the standard deviation of three independent
experiments. Significance was tested using a two-tailed t test assuming non-equal variance. In all cases p < 0.01.
(B) IFN treatment increases NO production in ISG15+/+ BMDM. NO production was quantified using the Griess
assay in the supernatant of ISG15+/+ or ISG15-/- BMDM detailed above. Results represent the mean ± the
standard deviation of three independent experiments. Significance was tested using a two-tailed t test assuming
non-equal variance. In all cases p < 0.01. (C) Viral production in infected ISG15+/+ BMDM in the presence of L-
arginine (0.5 mM). Results represent the mean ± the standard deviation of three independent experiments.
Significance was tested using a two-tailed t test assuming non-equal variance. In all cases p < 0.01. (D) NO
release in infected ISG15+/+ BMDM in the presence of L-arginine (0.5 mM). Results represent the mean ± the
standard deviation of three independent experiments. Significance was tested a two-tailed t test assuming non-
equal variance. In all cases p < 0.01.
https://doi.org/10.1371/journal.ppat.1006651.g006
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ISG15+/+ BMDM (Fig 5). Surprisingly, the collapse of mitochondrial stability and macro-
phage polarization in ISG15-/- BMDM corresponded with an advantage for viral replication
because an increase in viral titers was observed. Regarding the mitochondrial parameters
OXPHOS, ATP and ROS production, we found that IFN treatment produces an induction in
OXPHOS exclusively in ISG15+/+ BMDM (Fig 3). Given the demonstration that IFN triggers
an increase in OXPHOS [53] and in mitochondrial ROS production [54], our data clearly
indicate that IFN promotes these events via an ISG15-dependent mechanism, and thus
ISG15-/- BMDM could be desensitized to the actions of IFN. Moreover, we observed several
differences in the ETC organization from ISG15+/+ or ISG15-/- BMDM. Particularly, in
response to IFN treatment in ISG15-/- BMDM the ETC architecture was altered with a
decrease in the abundance of free CI and the presence of supercomplexes rearrangements
(Fig 3H). Although it is not known whether the ETC complexes can contribute to immune
function, recently it has been reported a critical role for mitochondrial ETC in innate
immune responses to bacterial infection [29]. Despite the massive mitochondrial ISGylation
observed after IFN treatment, no changes in ETC complexes in ISG15+/+ cells were observed
(Fig 3H), suggesting that changes in ETC complexes are not due to ISGylation of mitochon-
drial proteins. The mechanism by which ISG15 deficiency causes this ETC alteration will be
studied in the future.
Autophagic processes play a crucial role in cell-to-virus interaction [55] and are also critical
for cellular homeostasis by supporting cell survival and regulating inflammation [56]. Several
studies show that type I IFN induces autophagy by sequestering pathogens in autophagosome
vesicles that fuse with lysosomes, leading to their degradation [57]. In collaboration, we have
previously shown that ISG15 controls endosomal trafficking [58]. Specifically, ISGylation
blocks exosome secretion and this deficiency was rescued upon inhibition of autophagy, sup-
porting an important role for ISG15 in autophagy as recently described [59]. During mito-
phagy, damaged mitochondria are degraded by specific autophagy-lysosome pathways in the
autophagosome [40]. By confocal microscopy staining with an antibody specific anti-COX4
we observed remarkable differences in mitochondrial morphology in IFN-treated ISG15-/- vs
ISG15+/+ BMDM. In the absence of ISG15 and ISGylation the removal of damaged and dys-
functional mitochondria through mitophagy was clearly reduced (Fig 4C), which is dependent
on the fission/fusion cycle and is in line with the reduction in OXPHOS. Moreover, is
described that in damaged mitochondria, Parkin translocates from the cytoplasm to the outer
mitochondrial membrane to trigger mitophagy [42]. We also show that ISG15 controls Parkin
protein levels (Fig 4E), which is required for correct mitophagy initiation. Despite the low lev-
els of OXPHOS, the increased expression of mitochondrial proteins (Table 1 and Fig 4D) and
the mitophagy blockade in ISG15-/- BMDM (Fig 4C), may be a specific mechanism to compen-
sate for the loss of mitochondrial functionality, due perhaps to the lack of the proper ISGyla-
tion of mitochondrial components.
An additional activity of autophagy is to regulate apoptosis since it acts to clear dysfunc-
tional materials that are signals for cell death processes [60]. We previously showed that
VACV-infected ISG15-/- peritoneal macrophages are deficient in apoptosis as a clear reduction
was found in poly-(ADP-ribose) polymerase-1 (PARP-1) fragmentation and caspase activity
when compared to wild-type cells [22]. Along this line, our proteomic analysis revealed a
decrease in the expression of apoptosis-related proteins in ISG15-/- BMDM (Table 1), indicat-
ing that the loss of mitochondrial functionality provoked by the absence of ISG15 might be the
reason for the impairment in cell death.
Under normal conditions, mitophagy eliminates dysfunctional mitochondria, thereby con-
trolling levels of toxic ROS [37]. Poxvirus infection leads to an increase in ROS levels in the
host cell due to mitochondrial β-oxidation of palmitates, which are the main source of
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intermediates for the tricarboxylic acid cycle in the virus [61]. The effects of ROS during poxvi-
rus infection correlate with a decrease in translation fidelity [62]. Under physiological condi-
tions, ROS are produced as a normal byproduct of metabolism; however, exacerbated ROS
accumulation can cause vascular damage and inflammation by inducing the production of
proinflammatory cytokines [63, 64]. Thus, ROS levels act as a sensor for macrophage polariza-
tion, promoting an M1 phenotype [65]. Our data demonstrate the novel function of ISG15 in
controlling cellular metabolism and macrophage polarization. An imbalance in Arg-1 activa-
tion over iNOS activity, with a resultant depletion of intracellular L-arginine, could be respon-
sible for variations in infectious disease pathogenesis, as has been described for parasitic
infections [66–68]. While the role of Arg-1 in viral infections is not well understood, it has
been shown that Arg-1 overexpression blocks Chikungunya virus (CHIKV) clearance and tis-
sue pathology, suggesting a pathogenic role for Arg-1 after infection [69, 70]. Interestingly,
CHIKV-infected ISG15-/- mice present a dramatic increase in proinflammatory cytokines,
which contributes to their lethality [71]. This finding is in line with our results pointing to a
role for ISG15 in macrophage polarization by modulating L-arginine metabolism and proin-
flammatory cytokine induction.
Regarding the antiviral role of ISG15 against VACV, between one third and one half of
the 200 genes that form the VACV genome encode proteins with immunomodulatory roles
[72]. Some of these proteins have the ability to block IFN in a dual way as recently described
for the VACV C6 protein, which inhibits IFN signaling as well as type I IFN production [73].
In addition, we previously described that the viral E3 protein blocks protein ISGylation in
vitro [21]. The existence of these mechanisms is quite possibly the reason why the antiviral
role of ISG15 against VACV is limited, as several viral proteins can block IFN action. How-
ever, in the murine system when the ISGylation machinery is overexpressed prior to infec-
tion (S6 Fig) or when USP18-mutant cells are infected, where high levels of ISG15
conjugation are observed [16], viral titers decrease by more than one log (S6 Fig). This points
to a clear antiviral role for ISG15 after VACV infection [16]. We demonstrate here the novel
role of ISG15 in the fine-tuning of mitochondrial processes, which is associated with its anti-
viral capacities.
A proposed model for the role of ISG15 in the regulation of BMDM metabolism is
depicted in Fig 7. Briefly, IFN stimulates ISG15 production with a subsequent increase in
ISGylated proteins (Fig 2A). Following IFN treatment, ISGylated proteins are detected in
BMDM cytoplasm, nucleus and mitochondria (Fig 2B): 1. Proteomics indicate that several
mitochondrial processes are regulated by ISG15 (Table 1). Although we have not yet detected
which mitochondrial proteins are ISGylated, most of them appear not to be located in the
outer membrane (Fig 2C). IFN treatment produces an increase in OXPHOS (Fig 3A and 3B),
ATP production (Fig 3C) and ROS production (Fig 3E). 2. IFN treatment increases the pres-
ence of ATG and LC3B proteins, which are involved in autophagic processes (Fig 4A and
Table 1). 3. ISG15 controls Parkin protein levels required for correct mitophagy initiation
(Fig 4C). 4. Mitochondrial function is linked to polarization and vice versa. ISG15 blocks
Arg-1 at the mRNA (microarray data) and protein (Fig 5A and Table 1) level, and also blocks
its activity (Fig 5B), promoting NO production (Fig 6A) with a reduction in viral titer (Fig
6B).
These novel findings further underline the importance of ISG15 in the control of cellular
metabolism and the immune response. Nevertheless, a better understanding of how these dif-
ferent processes regulated by ISG15 may affect downstream immune functions in vivo will be
required to elucidate the complete role of ISG15 in the generation of protective responses dur-
ing infection with different pathogens.
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Materials and methods
Virus infections
VACV wild-type Western Reserve strain (WR) was grown on monkey BSC-40 cells (African
green monkey kidney cells, American Type Culture Collection (ATCC) number CRL-2761),
purified by sucrose gradient banding and titrated on BSC-40 cells as described [74]. VAC-
V-YFP, a generous gift of Michael Way, was grown as described [75].
Interferon treatment
Universal type I IFN (200 Units/ml) provided by PBL-Interferon Source was added to BMDM
cultures for 16 hours. Mice were treated intraperitoneally with 2000 Units/ g of IFN.
BMDM isolation
The origin of ISG15−/− mice has been described elsewhere [76]. Mice were sacrificed and both
tibias and femurs were collected. Bone marrow was flushed out using a syringe filled with
growth medium. Bone marrow cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) medium (Sigma), containing 10% fetal bovine serum (FBS; Sigma) and supple-
mented with macrophage colony-stimulating factor (M-CSF, PeproTech). Cultures were incu-
bated at 37˚C in a 5% CO2 atmosphere. After 5 days, non-adherent cells were removed and
adherent cells were used for experiments. To determine the purity of murine macrophages,
BMDM were incubated with antigen presenting cells-conjugated rat anti-mouse F4/80 anti-
bodies (eBioscience) prior to analysis by flow cytometry. The purity of isolated macrophages
varied between 90% and 95% in six separate experiments (S7 Fig).
Ethics statement
All animals were handled in strict accordance with good animal practice as defined by the rele-
vant national, international, and/or local animal welfare bodies, and with the Spanish Royal
Decree (RD 1201/2005). The Ethics Committee of Animal Experimentation of the UAM
approved all animal work. Animals were bred and housed under conventional conditions, the
project license number assigned by the ethics committee is PROEX 041/15.
Western blotting
BMDM were infected (106 cells/time post-infection; 1 PFU/cell) with VACV and collected at
the indicated times post-infection. Cell extracts were obtained using lysis buffer (50 mM Tris-
HCl, 0.5 M NaCl, 10% NP-40, 1% SDS) and protein extraction was performed for 5 min on
ice. Protein lysates (100 μg) were fractionated by 12% or 7.5% SDS-PAGE, transferred to nitro-
cellulose membranes, and incubated with the following primary antibodies: anti-ISG15, anti-
Arg-1 and anti-iNOS (Santa Cruz Biotechnology), anti-actin and anti-tubulin (Cell Signaling
Technology), anti-ATG3, anti-ATG5, anti-ATG7, anti-LC3B and anti-SDHA (Novus Biologi-
cals), anti-OPA-1, anti-CORE2 and anti-NDUFA9 (Abcam). Secondary antibodies were goat
peroxidase conjugates (Santa Cruz Biotechnology) and mouse and rabbit peroxidase conju-
gates (Sigma). Protein expression was detected using enhanced chemiluminescence (ECL)
reagents (Amersham). For the quantification Image J software was used and density of the spe-
cific band related to actin was represented.
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Mitochondria isolation
Mitochondria were isolated from BMDM as described elsewhere [29]. 1x108 BMDMs were
collected in phosphate buffered saline (PBS) supplemented with 5 mM EDTA and washed
with PBS. Cell pellets were frozen at −80˚C to increase cell breakage and were homogenized in
a tightly fitting glass-teflon homogenizer with 10 volumes of buffer A (83mM sucrose, 10 mM
MOPS, pH 7.2). An equal volume of buffer B (250 mM sucrose, 30 mM MOPS, pH 7.2) was
added and nuclei and unbroken cells were removed by centrifugation at 1000 g for 5 minutes.
Supernatants were collected and centrifuged at 12 000 g for 2 min. Mitochondria pellets were
washed once with buffer C (320 mM sucrose, EDTA 1 mM, 10 mM Tris-HCl, pH 7.4). Mito-
chondria were then suspended in an appropriate volume of PBS for storage at −80˚C.
Assessment of oxygen consumption and glycolytic flux
Real time oxygen consumption and extracellular acidification was conducted on BMDM (105
cells per well) using a XF-96 Extracellular Flux Analyzer (Seahorse Bioscience) as described
[29].
ATP synthesis assay
ATP synthesis was measured in permeabilized BMDM (106) by kinetic luminescence assay
as described [77]. Briefly, cells (2x106) were suspended in 160 μl of buffer A (150mM KCl,
25mM Tris-HCl, 2mM EDTA, 0.1% BSA FA, 10mM K-phosphate, 0.1mM MgCl2, pH 7.4) at
room temperature (RT) and 50 μg/ml digitonin was added. Samples were mixed gently for 1
min, and the reaction was stopped by addition of 1ml of buffer A. Cells were centrifuged at
3000 rpm for 2 min at RT, and pellets were suspended in 160 μl of buffer A and dispensed
into the wells of a 96-well luminescence reading plate (Costar). Substrate cocktail (50 μl) and
20 μl of buffer B (0.5M Tris-acetate, pH 7.75, 0.8mM luciferine, 20 μg/ml luciferase) were
added, and luminescence was measured over 1 min. Substrate cocktails were composed of 6
mM diadenosin pentaphosphate and 6 mM ADP supplemented with 1 M glutamate + 1 M
malate for determination of CI activity or with 1 M succinate for CII activity. ATP produc-
tion rate is expressed as ‘nmol of ATP/min/mg of protein.’ All measurements were per-
formed in triplicate.
Blue native gel
Mitochondrial isolated from ISG15+/+ or ISG15-/- BMDM treated or not with IFN(500 Units/
ml, 16 h), were harvested and 10 μl of sample buffer (5% Blue G-250, 5% glycerol in AA Buffer
(500 mM 6-aminohexanoic acid, 50 mM immidazole, 1 mM EDTA, pH 7)) was added. Sam-
ples were separated according to their indicated masses on a linear 3.5! 16% acrylamide gra-
dient gel for BN-PAGE, as was described [78], transferred to nitrocellulose membranes, and
incubated with the following primary antibodies anti-CORE2 for the complex III, anti-
NDUFA9, for complex I and ant-SDHA for complex II.
Citrate synthase activity
The activity of citrate synthase in total extract from ISG15+/+ or ISG15-/- BMDM treated or not
with IFN (500Units/ml, 16 h) were measured spectrophotometrically in a Beckman DU-650
spectrophotometer (Beckman Instruments) by monitoring the SH-CoA production. Protein
concentration was measured by the Lowry’s method. Specific activities were expressed as
nmol × min−1 × mg protein−1. All measurements were performed in triplicate.
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Quantification of mitochondrial DNA using real time PCR
mtDNA content was assessed by absolute quantification using real time PCR as described [79].
Primers for mouse mtDNA (mMitoF CTAGAAACCCCGAAACCAAA and mMitoR
CCAGCTATCACCAAGCTCGT) and mouse B2M (mB2MF ATGGGAAGCCGAACA
TACTG, mB2MR CAGTCTCAGTGGGGGTGAAT) were used to amplify the respective
products from mouse genomic DNA. mtDNA copy number per cell were determined from
template DNA by carrying out qPCR in a total volume of 10 μl, containing 5 μl of Quantifast
SYBR Master Mix (Qiagen), 0.5 μl of forward and reverse primer (400 nM final concentra-
tion each), 2 μl template DNA and 2 μl of DNase free water. The reactions were performed
in Roche LightCycler (LC) 480 instrument using the following protocol: pre-incubation at
95˚C for 5 min (1 cycle); denaturation at 95˚C for 10 s, annealing and extension at 60˚C for
30 s (repeat denaturation and extension steps for 40 cycles), melting at 95˚C for 5 s, 65˚C for
60 s, and 95˚C continues (melt curve analysis: 1 cycle) and the last step, cooling at 40˚C for
30 s.
MitoSOX imaging
BMDM were plated on 8-well chamber slides (ibidi) at a density of 200,000 cells/well. The cul-
ture medium was replaced with medium supplemented with MitoSOX Red mitochondrial
superoxide indicator (Life Technologies) at 10 μM during 1 hour in the dark. In some experi-
ments, 1 PFU/cell was also added to the medium. Culture dishes were washed with PBS,
replenished with culture medium and then imaged with an inverted confocal microscope, tak-
ing photographs each hour until 6 hpi. Image analysis was done with ImageJ. The fluorescence
was measured in several points of the well and was expressed as relative fluorescence per cell.
Proteinase K digestion
Isolated mitochondria from ISG15+/+ or ISG15-/- BMDM treated or not with IFN (25 μg each)
were resuspended in 20 mM Tris, pH 7.2, 15 mM KH2PO4, 20 mM MgSO4 and 0.6 M sorbitol
in a volume of 50 μl. Proteinase K was applied (final concentration of 50 or 250 μg/ml; Roche
Applied Science) for 15 min on ice. Alternatively ISG15+/+ isolated mitochondria were sub-
jected to proteinase K (50 μg/ml) proteolysis to digest in combination with increased digitonin
concentration. Osmotic shock (25 mM sucrose, 10 mM MOPS-KOH, pH 7.2) in the presence
of not of 1% TritonX-100 was used to disrupt the outer mitochondrial membrane. Addition of
PMSF to a final concentration of 5 mM was used to stop the reaction. Subsequently, mitochon-
drial vesicles were centrifuged at 6800×g for 3 min at 4˚C in a tabletop centrifuge and the pellet
was resuspended in SDS sample buffer containing 60 mM β-mercaptoethanol and boiled for 3
min at 95˚C.
Griess assay for NO
NO was determined by measuring nitrites in cell supernatants. Supernatants were combined
with an equal volume of sulphanilamide (10 mM; Sigma) and N-1 naphthyletliylenediamine
dihydrochloride (10 mM; Sigma) and incubated at room temperature for 5–10 min, and the
absorbance was measured at 490 nm in a microplate reader. Nitrite levels were determined
based on a standard curve of known concentrations of sodium nitrite.
Arginase assay
Arginase activity was assessed by measuring urea production with the Arginase Activity Assay
Kit (Sigma). Arginase activity was expressed in arbitrary units, where 1 unit equals the amount
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of enzyme needed to convert 1 micromole of L-arginine to ornithine and urea per minute at
pH 9.5 and 37˚C.
Fluorescence confocal microscopy
Cells were fixed and processed for immunofluorescence analysis. Briefly, cells were washed
with PBS, fixed with 4% PFA, and permeabilized with 0.1% Triton X-100 in PBS (room tem-
perature, 10 min). Localization of p62 and COX4 was performed using specifics antibodies
(Sigma and Abcam) and DNA was stained with ToPro 3 (Life Technologies). Images were
obtained using a Bio-Rad Radiance 2100 confocal laser microscope.
ELISA
Secreted IL-6 in the medium of BMDM was measured with the quantitative murine IL-6 kit
(BD Biosciences). Aliquots (100 μl) of supernatant from uninfected or BMDM at 2, 6, hpi were
used for ELISA according to the manufacturer’s instructions. Captured IL-6 was quantified at
450 nm with a spectrophotometer. Triplicate samples were measured in two independent
experiments.
Quantitative real-time PCR
Total RNA was extracted from macrophages and reverse-transcribed to cDNA using the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche). The mRNA expression of mouse TNF-α,
IFN-β, IL-6, IL-12β and IL-1β was detected by quantitative RT-PCR, which was performed in
a StepOnePlus Real-Time PCR System (Applied Biosystems) using iTaq Universal SYBR
Green Supermix (Bio-Rad). PCR cycling conditions were as follows: 1 cycle of 95˚C for 20 s
followed by 40 cycles of 95˚C for 3 s, and 60˚C for 30 s. Relative mRNA expression of target
genes was obtained by normalizing to 36B4 gene expression.
Proteomics analysis
Protein extracts from BMDM treated with IFN (500 Units/ml, 16 h), were obtained from cells
lysed in extraction buffer (50mM Tris-HCl, 1mM EDTA, 1.5% SDS, pH 8.5). Samples were
subjected to tryptic digestion and the resulting peptides were subjected to 4-plex isobaric label-
ing (iTRAQ) and separated into 8 fractions by cation exchange chromatography using Waters
Oasis MCX cartridges (Waters Corp, Milford, MA, USA) and graded concentrations of
ammonium formate, pH 3.0 (AF3) in acetonitrile (ACN). The tryptic peptide fractions were
subjected to nanoLC-MS/MS. High-resolution analysis was performed on a nano-HPLC Easy
nLC 1000 liquid chromatograph (Thermo Scientific, San Jose, CA, USA) coupled to an Orbi-
trap Fusion mass spectrometer (Thermo Scientific). Protein identification was performed
using the SEQUEST HT algorithm integrated in Proteome Discoverer 1.4 (Thermo Scientific).
MS/MS scans were matched against a mouse database (UniProtKB/Swiss-Prot 2015_11
Release). Peptides were identified from MS/MS data using the probability ratio method [80].
False discovery rate of peptide identifications was calculated by the refined method [81, 82]
Quantitative information was extracted from the MS/MS spectra of iTRAQ-labeled peptides.
For comparative analysis of protein abundance changes, we applied the Weighted Scan-Pep-
tide-Protein (WSPP) statistical workflow [83, 84] The quantified proteins were functionally
annotated using the Ingenuity Knowledge Database [85, 86] and DAVID [87]. The DAVID
repository includes 13 functional databases, including Gene Ontology, KEGG, and Panther.
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Ingenuity pathway analysis
To explore the differences in cellular protein dynamics regulated by ISG15, we used ingenuity
pathway analysis (IPA) (http://www.ingenuity.com/), which is a software platform that identi-
fies biological pathways and functions relevant to biomolecules of interest [88]. We uploaded
the proteins identified in the proteomic analysis and the ratio fold-change between ISG15-/-
and ISG15+/+ BMDM. Canonical pathway analysis identified the canonical pathways from the
IPA library that were most significant to our data set. The statistical significance of the associa-
tion between the data set and the canonical pathway was determined by Fisher´s exact test, for
which the p-value cutoff was set at 0.05 [89].
Supporting information
S1 Fig. Characterization of the energy metabolism of VACV-infected ISG15+/+ or ISG15-/-
BMDM. ISG15+/+ or ISG15-/- BMDM pretreated with IFN (500 units/ml, 16 hours) were
infected (1 PFU/cell) with VACV at the times indicated. OCR rates were monitored using the
Seahorse Biosciences extracellular flux analyzer. Four different biological replicates were mea-
sured and the value represents the mean.
(TIF)
S2 Fig. Glucose or galactose consumption is independent of ISG15. ISG15+/+ or ISG15-/-
BMDM treated with IFN (500 units/ml, 16 hours) were infected (1 PFU/cell) with VACV.
After infection, the medium was exchanged for a glucose- or galactose-enriched culture
medium. Analysis of the color change of the medium was quantified using a colorimetric assay
and represented as arbitrary units.
(TIF)
S3 Fig. Altered levels of autophagic and mitochondrial dynamism markers in ISG15-/-
BMDM. ISG15+/+ or ISG15-/- BMDMs treated or not with IFN (500 units/ml, 16 hours) were
infected (1 PFU/cell) with VACV at the times indicated. (A) Cellular lysates were analyzed by
12 or 7.5% SDS-PAGE followed by transfer to nitrocellulose membranes. The expression of
ATG-3, ATG-5, ATG-7, LC3-B and β-actin (protein loading control) was detected by western
blotting using specific antibodies and graphs represents quantification of each protein normal-
ized with actin levels obtained from IFN-I-treated and untreated cells in two independent
experiments. (B) Cellular lysates were analyzed by 12 or 7,5% SDS-PAGE, transferred to nitro-
cellulose membranes and the expression of OPA-1, SDHA and tubulin (protein loading con-
trol) were detected by Western blot using specific antibodies, graphs in the bottom represents
quantification of each protein normalized with actin levels obtained from IFN-I-treated and
untreated cells in two independent experiments.
(TIF)
S4 Fig. Exogenous polarization is independent of ISG15. ISG15+/+ and ISG15-/- BMDM were
polarized to M1 using 10 ng/ml IFN-γ (PeproTech) and LPS (Sigma) or to M2 with 10 ng/ml
IL-4 (PeproTech) for 8 hours. After this, cells were infected with VACV (1 PFU/cell) for the
times indicated. Cellular lysates were analyzed by 12% SDS-PAGE, transferred to nitrocellu-
lose membranes and the expression of iNOS, Arg-1, ISG15 or actin (protein loading control)
was detected by western blotting using specific antibodies.
(TIF)
S5 Fig. VACV replication assessment in ISG15+/+ and ISG15-/- BMDM and in HeLa cells.
(A, B) One-step VACV-YFP growth in infected (1 PFU/cell) ISG15+/+ and ISG15-/- BMDM
and HeLa cells treated or not with IFN (500 units/ml, 16 hours). Cells were infected and
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fluorescence due to viral replication was visualized by fluorescent microscopy at the times
indicated (A); cells were harvested and virus yields were determined by plaque assay (B).
Results represent the mean ± standard deviation of three independent experiments. Signifi-
cance was tested using a two-tailed t test assuming non-equal variance. In all the cases
p< 0.01. HeLa cells were used as a control of viral growth and IFN resistance. (C) Viral growth
was also detected by immunofluorescence in BMDM treated or not with IFN (500 units/ml, 16
hours) and infected for 24 hours with VACV (1 PFU/cell). Cells were grown in coverslips,
fixed with 4% PFA and processed for microscopy. Actin filaments were stained with phalloidin
(red), DNA was stained with Topro (blue), and viral protein A27 was visualized using a spe-
cific antibody. Images show representative fields (×73 magnification).
(TIF)
S6 Fig. Overexpression of murine ISGylation machinery reduces VACV replication. 293T
cells were cotransfected with the murine E1, E2, E3, and GG-ISG15 and at 24 hours post transfec-
tion infected with VACV (1 PFU/cell). At 24 h post infection viral titter was analysed by plaque
assay. Results represent the mean ± standard deviation of three independent experiments. Signifi-
cance was tested using a two-tailed t test assuming non-equal variance. In all the cases p< 0.01
(TIF)
S7 Fig. Control of VACV infection and BMDM purity using a specific anti-F4/80 macro-
phage marker antibody and VACV-YFP. ISG15+/+ and ISG15-/- BMDM were infected with
VACV-YFP (1PFU/cell) and at 24 hpi cells were collected and processed for flow cytometry.
(A, B) Uninfected ISG15+/+ (A) or ISG15-/- (B) BMDM were 97% positive for F4/80 antibody.
No signal for YFP was detected. (C, D) ISG15+/+ (C) or ISG15-/- (D) BMDM infected for 24
hours with VACV-YFP (1 PFU/cell) were 80 or 88%, respectively, double positive for F4/80
and YFP, indicating that the majority of BMDM were infected with VACV-YFP.
(TIF)
S1 Table. Genes regulated by ISG15 in infected macrophages. Comparison of gene expres-
sion profile (microarray analysis) of ISG15+/+ and ISG15-/- peritoneal macrophages pre-treated
with IFN (500 units/ml, 16 hours) and infected with VACV (1PFU/cell) for 6 hours. Gene
symbol, description and x-fold change in expression are indicated.
(TIF)
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